Initial clinical response data for AlloNK in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food and Drug Administration (FDA) interaction to discuss potential pivotal trial ...

Anti-inflammatory therapies that are highly effective for inflammatory skin diseases might also be relevant to depression because of shared inflammatory pathways.